Boehringer and CDR-Life report data from geographic atrophy treatment trial
Boehringer Ingelheim and CDR-Life have reported positive outcomes from the Phase I clinical trial of BI 771716, a new treatment…
Boehringer Ingelheim and CDR-Life have reported positive outcomes from the Phase I clinical trial of BI 771716, a new treatment…
MSD (Merck & Co) and its wholly-owned subsidiary EyeBio have announced the start of the Phase IIb/III BRUNELLO clinical trial…
The US Food and Drug Administration (FDA) has granted clearance for BlueRock Therapeutics’ investigational new drug (IND) application to commence…
The US Food and Drug Administration (FDA) has granted clearance for Find Therapeutics' investigational new drug (IND) application to commence…
Aldeyra Therapeutics has met the primary endpoint in a Phase III clinical trial of the Reproxalap drug for dry eye…
Viridian Therapeutics has announced the completion of subject enrolment for its Phase III THRIVE-2 clinical trial of VRDN-001, aimed at…
Alkeus Pharmaceuticals has reported the latest interim data from TEASE-3 trial where gildeuretinol acetate demonstrated to stall the progression of…
Roche has announced four-year results from the RHONE-X extension study, which evaluated the long-term safety and efficacy of Vabysmo (faricimab)…
Aldeyra Therapeutics has concluded the subject enrolment in its Phase III clinical trial of topical ocular 0.25% reproxalap, a new…
US-based biotechnology company Viridian Therapeutics has announced plans to begin two Phase III clinical trials of the anti-IGF-1R antibody, VRDN-003,…